I. Synthetic polymer-based anticancer prodrugs
Jindrich Kopecek (Departments of Pharmaceutics and Pharmaceutical Chemistry and of Bioengineering, University of Utah, Salt Lake City, Utah 84112)
HPMA-anticancer drug conjugates
Richard B. Greenwald (Enzon Pharmaceuticals, Inc., 20 Kingsbridge Road, Piscataway, New Jersey 00854)
Poly(ethylene glycol)-anticancer drug conjugates
Chun Li (Department of Experimental Diagnostic Imaging, Box 59, The University of Texas, M.D. Anderson Cancer Center,
1515 Holcombe Blvd., Houston, TX 77030, USA)
Poly(L-glutamic acid)-anticancer drug conjugates
II. Natural polymer-based anticancer prodrugs
Felix Kratz (Department of Medical Oncology, Clinical Research, Tumor Biology Center, Breisacher Straße 117, D-79106 Freiburg, Federal Republic of Germany)
Protein-based anticancer conjugates
Andrew V. Schally (Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, Louisiana)
Peptide and peptide hormone anticancer therapeutics
Yoshiharu Machida (Department of Drug Delivery Research, Hoshi University; 2-4-41 Ebara, Shinagawa-ku, Tokyo 142-8501, Japan)
Chitosan and other polysaccharide anticancer conjugates
III. Antibody-directed cancer therapy
John R. Desjarlais
Xencor, Inc. CA 91016, United States
Engineering of antitumor antibodies
Victor S. Goldmacher (ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA)
Antibody-anticancer drug conjugates
David M. Goldenberg (Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ 07109, USA.)
Immunoconjugate and radioimmunoconjugate anticancer therapeutics
Kenneth D. Bagshawe (Imperial College London, Department of Medical Oncology, Charing Cross Campus, Fulham Palace Road, London W6 8RF, UK.)
Antibody-directed enzyme prodrug anticancer therapeutics
Paul M. Harari (University of Wisconsin Medical School and Comprehensive Cancer Center, Madison, WI 53792, USA.)
EGFR-directed monoclonal antibodies
Gabriel N. Hortobagyi (Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX. usa)
Her2/neu-directed antibodies
John M. Kirkwood (Division of Hematology-Oncology, Department of Medicine, Hillman Cancer Center, Pittsburgh, PA 15232)
CTLA-4-directed monoclonal antibodies
Dario Neri (Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland)
Antibodies directed to tumor vasculature
IV. Lipid-based anticancer prodrugs
L. Harivardhan Reddy, Patrick Couvreur (Physicochimie, Pharmacotechnie et Biopharmacie, Faculty of Pharmacy, Universite Paris-Sud XI, Chatenay-Malabry, France)
Lipid-based prodrugs of anti-metabolite anticancer agents
Mitsuru Hashida (Department of Drug Delivery Research, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan)
Lipid-based prodrugs of non-anti-metabolite anticancer agents
V. Macromolecular nucleic acid therapeutics
Ernst Wagner (Pharmaceutical Biology-Biotechnology, Department of Pharmacy, Ludwig-Maximilians-Universitaet, Butenandtstr. 5-13, D-81377, Muenchen, Germany)
Macromolecular nucleic acid therapeutics
Uwe Zangemeister-Wittke (Department of Pharmacology, University of Bern, Bern, Switzerland.)
Antisense oligonucleotides
Brett P. Monia (Isis Pharmaceuticals, California 92008, USA)
Therapeutic MicroRNAs
Mark A. Behlke (Integrated DNA Technologies Inc., Coralville, IA 52241, USA)
Therapeut
About the Author:
L. Harivardhan Reddy is Head of Nanovectors group at Sanofi-aventis, France. He completed Ph.D. in Pharmaceutics and Drug delivery in 2005 from The M.S. University of Baroda, India. He has worked for 4 years in two popular pharmaceutical companies (Sun Pharmaceutical Industries Ltd., and Aristo Pharmaceuticals Ltd.) in India, on drug delivery applications. He worked for 3 years (2005-2008) with anticancer drug delivery specialist Prof. Patrick Couvreur in CNRS lab at Université Paris-Sud, Chatenay-Malabry, France. He is an inventor of 3 patents belonging to macromolecular therapeutics and drug delivery. He has published, as an author and co-author, more than 60 publications in various reputed journals. He is also a reviewer for more than 15 journals of the fields of biomacromolecules, drug delivery, cancer therapy, and pharmacology. He is a member of The European Association for Cancer Research. His principal research interests are supramolecular lipidic prodrug nanomedicines and nanotherapeutics for cancer.
Patrick Couvreur is a Full Professor of Pharmacy at the University Paris-Sud, France, and holder of the chair of "Innovation Technologique" (2009-2010) at the prestigious 'Collège de France'. He is a member of the Academy of Technologies (France), of the Academy of Pharmacy (France) and corresponding member of the Royal Academy of Medicine (Belgium). Prof. Patrick COUVREUR's contributions in the field of drug delivery and targeting are highly recognized and respected around the world. Patrick COUVREUR performed a pioneer work together with Peter SPEISER, and demonstrated for the first time in 1977 that nanoparticles may be used as intracellular carriers for compounds which don't diffuse spontaneously into cells. Patrick COUVREUR's research is primarily on polymer-based and metallic-based nanomedicines, surface engineered nanosystems, and also focuses on lipid-based nanocarriers. He has published as an author and co-author, 341 publications, 109 review articles and book chapters, 6 books as editor, 50 patents, and 193 invited and plenary lectures at national and international congresses. He has received Pharmaceutical Sciences World Congress Award (2004), the "Marie-Maurice Janot Lecture" (2008) and above all the prestigious "Host Madsen Medal" (2007) in honour of his outstanding research achievements. He is a Field Editor of "Pharmaceutical Research", European Editor of the "Journal of Nanoparticles Research", and is a reviewer of more than 15 high reputed journals in the fields of Drug delivery, cancer research, macromolecules, physical chemistry etc. He is acting or acted as Board of Governors of the Controlled Release Society (CRS), Board of APGI, Expert Member of the Board of Pharmaceutical Sciences, International Pharmaceutical Federation (FIP). His exceptional research has led to two start-up companies BIOALLIANCE and MEDSQUAL dealing with novel therapeutics, in France.
